You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 6, June 1976 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOUTHERN CALIFORNIA CHAPTER OF THE AMERICAN COLLEGE OF SURGEONS, SANTA BARBARA, CALIF, JAN 16-18, 1976
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antithymocyte Globulin in Renal Transplant Recipients

Report of a Prospective Randomized Controlled Trial

Satya N. Chatterjee, MD, FRCS(Eng, Edin, Glas)

Arch Surg. 1976;111(6):680-683.


Abstract

• Horse antihuman thymocyte globulin (HAHTG) combined with prednisone and azathioprine (Imuran) was used as immunosuppressive therapy in a randomized controlled study in 50 renal allograft recipients. Side effects of HAHTG administration given intravenously were mostly mild. In the treated group, four patients out of 26 died of infectious complications, whereas in the control group, three patients out of 24 died of infectious complications ({chi}2 =.01, P >.05). The graft survival at 18 months was ten of 24 in the control group and ten of 26 in the treated group ({chi}2 = 1.26, P >.05). Cumulative graft survival was 58.3% in the control group and 38.1% in the treated group at 18 months. However, if we consider the people who died with a functioning graft not as graft failure but as if they left the study, then the cumulative graft survival is 64.5% in the control group and 65.9% in the treated group. Thus, the mortality from infective causes and graft survival were not significantly different between the two groups. Hence, we draw the conclusion that use of HAHTG did not exert a beneficial effect on the ultimate outcome.

(Arch Surg 111:680-683, 1976)



Author Affiliations

From the Department of Surgery, Los Angeles County-University of Southern California Medical Center, Los Angeles.


Footnotes

Accepted for publication Feb 27, 1976.

Read before the annual meeting of the Southern California Chapter of the American College of Surgeons, Newport Beach, Calif, Jan 17, 1976.

Reprint requests to Charles Drew Postgraduate Medical School, 12021 S Wilmington Ave, Los Angeles, CA 90059 (Dr Chatterjee).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Primary Cytomegalovirus and Opportunistic Infections: Incidence in Renal Transplant Recipients
Chatterjee et al.
JAMA 1978;240:2446-2449.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1976 American Medical Association. All Rights Reserved.